Resverlogix Corp.
Research Resverlogix Corp. (RVX) on Bullrun: market cap CAD 33.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVX
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 33.28M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 3.45M
- Free cash flow-USD 1.19M
Valuation Snapshot
latest market cap is CAD 33.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 7.77M | -USD 4.36M | n/a | n/a | USD 108.00K | USD 20.80M | -USD 88.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | CAD 33.28M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Resverlogix Corp.'s market cap?
Resverlogix Corp.'s market capitalization is CAD 33.28M.
What does Resverlogix Corp. do?
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions.